TRX2

TRX2 is a hair supplement brand developed and sold by Oxford Biolabs Ltd, a nutraceutical and cosmeceutical company based at the Oxford Science Park in Oxford, United Kingdom. Its flagship product is an oral capsule marketed to men and women with thinning hair, built around a proprietary complex the company says supports the potassium ion channels in hair follicles. The brand remains active, with a live catalogue and multiple regional storefronts as of 2026.

The company traces its origins to research at the University of Oxford. In 2008, biochemist Dr. Thomas Whitfield examined the role of potassium channels in hair growth, work the company describes as the cornerstone of its flagship product [3]. Oxford Biolabs was founded by former University of Oxford scientists to develop naturally-based products for hair loss, premature greying and skin ageing.

Oxford Biolabs was established to turn academic work on hair-follicle biology into consumer products. Dr. Thomas Whitfield, who holds a doctorate in biochemistry from Oxford, is credited as founder. The company's stated foundation rests on the idea that as hair loss progresses, the activity of potassium channels within the follicle diminishes; the TRX2 formula is presented as a way to help maintain their normal function.

Sources disagree on when the company began. Oxford Biolabs states on its own pages that it was "established in 2009" [3], while Wikipedia records it as "Founded in August 2008" [7]. The underlying potassium-channel research is dated to 2008 in both accounts, so the gap likely reflects the difference between when the research started and when the company was formally established.

The TRX2 formula was completed and launched as the company's flagship molecular food supplement for hair around the start of the 2010s. Here too the sources differ on the exact year: the company dates the launch to 2010 [3], while Wikipedia states the supplement was "marketed in 2011" [7]. Oxford scientists reported completing an initial clinical study with positive outcomes shortly after.

The line grew over the following decade. In 2015 the company added a Hair Revitalising Foam and Lotion alongside Melaniq, a supplement aimed at hair pigmentation. A skin supplement, DRM4, followed in 2017, and a hair-inhibition system named Mepilarin was introduced in 2021.

TRX2 is owned and operated by Oxford Biolabs Ltd, which sells the brand directly. The company describes itself as an independent "product and brand creator and developer" rather than part of a larger group, and no acquisitions are recorded.

Oxford Biolabs positions itself as a science-led company that favours naturally-based formulas over drug-based ones. Its stated mission is to "truthfully engage our customers with credible science and great products" [2], and it frames its products as addressing visible signs of ageing such as hair loss, greying and skin ageing. The TRX2 tagline used on its collection pages is "The treatment. Finally arrived."

An independent 2022 retrospective by the Hair Loss Review Centre placed the product more narrowly, describing it as a "hair health supplement" rather than a hair loss treatment and stating plainly that "it is not a treatment for baldness" [8]. The same review noted that TRX2 is marketed as a preventative supplement for early-stage thinning rather than a clinical treatment on the level of minoxidil or finasteride.

The core product is the TRX2 Molecular Food Supplement for Hair, an oral capsule taken three times a day. Its formula combines potassium chloride, Carnipure (a branded form of L-carnitine-L-tartrate), branched-chain amino acids, nicotinic acid and biotin, together with zinc and selenium. The company centres its marketing on a proprietary potassium channel-stimulating complex, which it says helps maintain normal, healthy hair at a molecular level.

Beyond the flagship capsule, the wider range includes a Hair Revitalising Lotion, shampoos, a conditioner, a foam and a thickening cream, plus the Melaniq pigmentation supplement and the DRM4 skin line. Oxford Biolabs states that the supplement is developed in Oxford and manufactured in Germany at an EU-licensed plant, and describes it as cruelty-free, suitable for vegetarians, and free from gluten and preservatives, though it cites no formal certification body.

On efficacy, the company reports that "87% of people reported significant improvement after using TRX2" in a randomised, double-blind, placebo-controlled study [4]. Wikipedia describes an 18-month study in which 59 volunteers showing signs of alopecia received either TRX2 or a placebo, with 26 of the TRX2 participants recording at least a 10% increase in hair strands or hair weight [7]. Third-party testing has been carried out through the German institute Dermatest.

Oxford Biolabs lists a range of publications on its own "as seen in" media page, including The Telegraph, GQ, Esquire, Tatler, Men's Health and the Daily Mail, and cites a CBS News feature titled "Pharma's 4 Best Shots at a Cure for Baldness." These are the company's own self-reported press mentions rather than independently verified coverage.

In January 2014 the UK Advertising Standards Authority upheld a complaint against TRX2 and Oxford Biolabs, ruling that the company's advertisements were misleading and in breach of EU advertising codes. The company agreed with the ruling and amended its advertising accordingly [7].

The brand is active. Oxford Biolabs maintains a live website with US, UK and international storefronts and a priced catalogue, and the company states TRX2 has been sold in more than 110 countries. The most recent dated product milestone is the 2021 introduction of Mepilarin. The 2022 Hair Loss Review Centre assessment noted that the product saw its strongest commercial period between roughly 2012 and 2016, with a decline afterward, while observing that it has remained on the market for over a decade [8].